Research Paper Volume 12, Issue 22 pp 23114—23128

Figure 1. Expression of EMT-related proteins after treatment with the recombinant human S100A9 protein and AKT1 inhibitor. (A) After incubation with different concentrations of recombinant human S100A9 protein for 24, 48, 72 and 96h, the viability of HP75 cells was assessed using CCK-8(n=5. P<0.01^**; P<0.001^***, compared with the group with 10μg/mL recombinant S100A9 protein at the same time point). (B) HP75 cells were divided into control group, 10μg/mL recombinant S100A9 protein group and 10μg/mL recombinant S100A9 protein+ A-674563 group, the levels of p-AKT1^Thr308, Vimentin, ICAM-1 and E-cadherin were observed using western blot(n=5. P<0.01^**; P<0.001^*** versus control group. P<0.001^### versus 10μg/mL recombinant S100A9 protein+ A-674563 group).